Reversing Bone Loss with Alendronate in HIV-Infected Patients

In a randomized, placebo-controlled trial, weekly alendronate safely improved bone-mineral density among osteopenic HIV-infected patients receiving antiretroviral therapy.

Decreased bone-mineral density (BMD) seems to be common among HIV-infected patients. Possible determinants include the duration and severity of HIV infection, type and duration of antiretroviral therapy (ART), menopausal status, hormone levels, and smoking status. In the general population, calcium, vitamin D, and bisphosphonates improve BMD and reduce the risk for fractures. Is this combination also beneficial in HIV-infected patients?

To address this question, investigators conducted a double-blind, placebo-controlled trial of twice-daily calcium and vitamin D, with or without weekly alendronate (70 mg), among 82 HIV-infected patients who were receiving stable ART, had lumbar spine T scores of –1.5 or lower, and had no secondary causes of …

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Reversing Bone Loss with Alendronate in HIV-Infected Patients

Topics

Reviewing Author